GLI2 and acute myeloid leukemia: Most notably, one patient with refractory AML treated with MBZ monotherapy in an off-label setting responded with a clear and continuous decrease in leukemic blasts in peripheral blood and a fast reduction in GLI2 levels in peripheral leukemic blood cells.